Endometrial cancer starts in the lining of the uterus and is the most common gynecologic cancer. It often causes abnormal vaginal bleeding, especially after menopause, and pelvic pain or discharge can occur. Most people with endometrial cancer are diagnosed after menopause, but it can affect younger people with risk factors like obesity or certain hormone exposures. Treatment usually includes surgery to remove the uterus, and some need radiation, hormone therapy, or chemotherapy. Survival is good when endometrial cancer is found early, but advanced disease can be serious.
Overview
Endometrial cancerSymptoms
Endometrial cancer often causes abnormal vaginal bleeding—between periods, heavy periods, or any bleeding after menopause. You may notice watery or blood-tinged discharge, pelvic pain or pressure, pain during sex, or fatigue. Early symptoms of endometrial cancer are usually bleeding changes.
Outlook and prognosis
Most people diagnosed with endometrial cancer at an early stage do well, especially when surgery removes all visible disease. Outlook depends on stage, tumor type, and overall health, and can vary from highly curable to more complex. Regular follow-up, weight management, and tailored treatments help maintain long-term health.
Causes and risk factors
Risk rises with age, obesity, and long estrogen exposure (early periods, late menopause, no pregnancies, polycystic ovary syndrome). Diabetes, inactivity, estrogen-only hormone therapy or tamoxifen, endometrial hyperplasia, prior pelvic radiation, and inherited risk (Lynch syndrome) also increase endometrial cancer risk.
Genetic influences
Genetics play a meaningful role in endometrial cancer, especially with inherited syndromes like Lynch syndrome. Family history can raise risk, and certain gene variations affect how the cancer starts and grows. Genetic testing may guide screening and treatment choices.
Diagnosis
Endometrial cancer is often investigated after abnormal uterine bleeding using a pelvic exam and transvaginal ultrasound. Definitive diagnosis of endometrial cancer requires an endometrial biopsy; hysteroscopy or dilation and curettage may assist, and MRI or CT helps stage disease.
Treatment and drugs
Treatment for endometrial cancer often starts with surgery to remove the uterus (hysterectomy), usually with the ovaries and fallopian tubes. Depending on stage and tumor features, doctors may add radiation, chemotherapy, or hormone therapy. Targeted or immunotherapy can help in select cases after tumor testing.
Symptoms
Unexpected vaginal bleeding is often the first clue, especially bleeding after menopause or spotting between periods. Early symptoms of endometrial cancer can also include a watery, blood-tinged discharge or new pelvic discomfort. A healthcare professional can help sort out what’s typical aging and what warrants a closer look. Endometrial cancer tends to cause symptoms early, which is why any new bleeding should be checked.
Any bleeding after going 12 months without periods is not typical. Even light spotting after menopause should be checked promptly. It can be an early sign of endometrial cancer, though other causes are common.
Periods that are heavier than usual, last longer than 7 days, or require changing pads or tampons very often can signal a problem. These changes may be due to hormones, fibroids, or endometrial cancer.
Bleeding between cycles or after sex may show up as pink or brown staining. When new for you or persistent, it deserves evaluation. Sometimes this can be related to endometrial cancer.
A thin, watery, or blood-tinged vaginal discharge can appear days or weeks before noticeable bleeding. Some notice a persistent dampness or need to wear a liner. This can occur with endometrial cancer or with infections and other conditions.
How people usually first notice Endometrial cancer?
Many people first notice endometrial cancer when vaginal bleeding changes—most often new bleeding after menopause, or heavier, longer, or irregular periods before menopause. Some also spot watery or blood-tinged discharge or feel pelvic discomfort or cramps that don’t match their usual pattern. Any unexpected bleeding—especially after menopause—is a common early warning and a reason to see a clinician promptly.
Types of Endometrial cancer
Endometrial cancer has a few well-recognized types that behave differently and may cause different symptom patterns over time. Doctors define these by how the cells look under the microscope and by common gene changes found in the tumor. People may notice different sets of symptoms depending on their situation. Knowing the main types of endometrial cancer can help you understand why one person’s plan may look different from another’s.
Endometrioid type
This is the most common type and often linked with excess estrogen exposure. Many notice abnormal uterine bleeding early, which can lead to earlier diagnosis.
Serous type
This less common type tends to be more aggressive and can spread sooner. Bleeding may be lighter or later, and symptoms can include pelvic pain or bloating.
Clear cell type
This rare type can behave more aggressively than the endometrioid type. Symptoms may include postmenopausal bleeding and pelvic discomfort.
Carcinosarcoma
Also called malignant mixed Müllerian tumor, this is a high-grade cancer with both glandular and sarcoma-like components. It often presents with bleeding plus pain or a mass.
POLE-ultramutated
Defined by a POLE gene mutation, this molecular subtype often has an excellent outlook despite high-grade features. It may present with abnormal bleeding similar to other types.
MSI-high/dMMR
Tumors with mismatch repair deficiency can respond to immunotherapy. Bleeding is common; a family history of Lynch syndrome may be a clue.
p53-abnormal
Often overlapping with serous histology, these tumors have TP53 abnormalities and tend to be more aggressive. Symptoms can be subtle at first, with later pelvic pain or pressure.
NSMP (no specific molecular profile)
These tumors lack the other hallmark molecular changes and vary in behavior. They often resemble endometrioid cancers with abnormal bleeding as a key sign.
What genetics can tell you about symptoms
Some inherited changes in DNA repair genes like MLH1 and MSH2 (Lynch syndrome) raise the chance of endometrial cancer that appears younger, with abnormal uterine bleeding and sometimes cancers in the colon or ovaries. PTEN mutations (Cowden syndrome) can link heavy, irregular bleeding with earlier, multiple uterine polyps.
Causes and risk factors
Long-term exposure to high estrogen without enough progesterone is a key driver. Endometrial cancer risk rises with age, especially after menopause. Key risk factors for endometrial cancer include being overweight or inactive. Some cases run in families due to inherited gene changes such as Lynch syndrome, and past pelvic radiation or estrogen-only hormone therapy can raise risk. Doctors distinguish between risk factors you can change and those you can’t.
Environmental and biological risk factors
Understanding what raises risk can help you seek care promptly and plan checkups. Doctors often group risks into internal (biological) and external (environmental). For endometrial cancer, many risks relate to how much estrogen the uterus lining is exposed to over time. This awareness can also help you act quickly if early symptoms of endometrial cancer ever appear.
The chance of endometrial cancer rises as people get older, especially after menopause. Hormone shifts after the last period can leave the uterine lining more sensitive to estrogen.
Starting periods early or reaching menopause later gives the uterine lining more years of estrogen exposure. This longer exposure window increases risk for endometrial cancer.
Estrogen without enough progesterone can make the uterine lining grow and thicken. Over time, this unbalanced hormone effect raises the risk of endometrial cancer.
Using estrogen-only hormone therapy after menopause stimulates the uterine lining. Without added progesterone, longer use is linked to a higher risk of endometrial cancer.
Genetic risk factors
A portion of endometrial cancer is linked to inherited changes in certain genes. Some risk factors are inherited through our genes. Knowing the key genetic causes can help families decide if genetic testing for endometrial cancer risk makes sense. Not everyone with a mutation will develop cancer, and risks vary by the gene involved.
Lynch syndrome: Inherited changes in MLH1, MSH2, MSH6, PMS2, or EPCAM can impair DNA repair. Lifetime risk for endometrial cancer can range from about 15% to over 50%, depending on the gene. Relatives may also be at risk if they share the same gene change.
Lynch gene differences: Endometrial cancer risk is typically highest with MLH1 or MSH2, moderate with MSH6, and lower with PMS2. People with MSH6 or PMS2 changes may be diagnosed later in life and sometimes have endometrial cancer as the first sign. These differences help interpret risk patterns within families.
PTEN/Cowden syndrome: Inherited PTEN changes can raise lifetime risk of endometrial cancer, often beginning in adulthood. Many also have benign growths and thyroid or breast findings that prompt testing. Families with a known PTEN change can pass it from one generation to the next.
POLE/POLD1 variants: Specific changes in the DNA proofreading region of POLE or POLD1 can markedly increase endometrial cancer risk. People may develop numerous colon polyps and colorectal cancer as well. Cancer risk often starts in mid-adulthood.
Family history patterns: Endometrial or colorectal cancers across generations, especially under age 50, can signal an inherited cause. Even without a confirmed mutation, a first-degree relative with endometrial cancer can raise your personal risk. A genetics professional can help assess which genes to test.
Lifestyle risk factors
Lifestyle can meaningfully shift endometrial cancer risk by influencing estrogen, insulin, and inflammation. Among the lifestyle risk factors for endometrial cancer, excess body fat and inactivity are the most established. Diet patterns that drive weight gain or insulin resistance also matter. Small, sustained changes that reduce adiposity and improve metabolic health can lower risk over time.
Adipose tissue converts and stores estrogen, raising unopposed estrogen exposure to the uterine lining. Higher body mass index is strongly linked to higher endometrial cancer risk. Even modest, sustained weight loss can meaningfully reduce risk.
Gaining weight after age 18 increases risk independent of starting weight. Rapid or continued midlife weight gain raises estrogen and insulin signaling that promote endometrial cell growth.
Little to no moderate-to-vigorous activity is associated with higher risk. Regular movement improves insulin sensitivity and lowers chronic inflammation that can stimulate endometrial proliferation.
Long periods of sitting impair glucose and insulin regulation even if you exercise some. Breaking up sitting with brief movement can improve metabolic markers tied to endometrial cancer risk.
Risk prevention
Endometrial cancer risk can be lowered by managing weight, hormones, and metabolic health, and by knowing when to seek care for unusual bleeding. There’s no routine screening test for everyone, but people with higher inherited risk may benefit from tailored monitoring or preventive surgery after completing family plans. Prevention works best when combined with regular check-ups.
Keeping weight in a healthy range lowers estrogen made by body fat and eases inflammation. Even modest, steady weight loss can reduce risk over time.
Aim for daily movement that gets your heart rate up, like brisk walking or cycling. Exercise helps regulate hormones and insulin, which can protect the uterine lining.
Keep blood sugar in target range and treat insulin resistance. Good diabetes management lowers growth signals that can affect the uterine lining.
If you use estrogen for menopause and still have a uterus, add a progestin to protect against endometrial cancer. Review risks and benefits regularly with your clinician.
Transmission
Endometrial cancer is not contagious—it cannot be passed from one person to another through everyday contact, sex, or body fluids. Most endometrial cancer happens by chance over time, not through inheritance, but a small portion runs in families because of an inherited gene change that raises risk. In families with a known syndrome such as Lynch syndrome or Cowden syndrome, it’s the risk—not the cancer itself—that is passed down, and each child has about a 50% (1 in 2) chance to inherit the gene change. Inheriting such a change does not mean someone will definitely develop endometrial cancer, but it can increase lifetime risk. If you’re concerned about how endometrial cancer is inherited or have a strong family history, a genetics professional can explain your options and who in the family may benefit from testing.
When to test your genes
Consider genetic testing if you developed endometrial cancer before age 50, have a strong family history of related cancers (uterine, colorectal, ovarian), or have tumors showing mismatch repair deficiency. Testing can pinpoint Lynch syndrome and guide screening, treatment, and prevention for you and relatives. Ask your oncology team or a genetic counselor.
Diagnosis
Many people first notice abnormal uterine bleeding, spotting between periods, or bleeding after menopause, which prompts a check-up. Doctors usually begin with a focused history and pelvic exam and then move to tests that look at the uterine lining. The diagnosis of endometrial cancer is confirmed by examining a tissue sample from the uterus under a microscope. Some tests also help show how far the cancer has spread and guide the treatment plan.
Your provider asks about bleeding patterns, pain, and risk factors, then performs a pelvic exam. This helps decide which tests to do next.
A small probe uses sound waves to measure the thickness of the uterine lining. A thicker-than-expected lining, especially after menopause, suggests the need for a biopsy.
A thin tube removes a small tissue sample from the uterine lining in the office. Looking at this tissue under a microscope confirms or rules out endometrial cancer.
A tiny camera is inserted through the cervix to view the inside of the uterus. This allows the doctor to target biopsies to any areas that look unusual.
Stages of Endometrial cancer
Endometrial cancer is grouped into stages based on how far it has spread in the body. Early and accurate diagnosis helps you plan ahead with confidence. Staging is usually confirmed after surgery and review of tissue, along with imaging scans. Many seek care after early symptoms of endometrial cancer such as unexpected vaginal bleeding.
Stage I
Cancer is only in the uterus. It may grow into the muscle wall but has not moved beyond the uterus.
Stage II
Cancer has spread from the uterus into the cervix. It has not grown outside the uterus.
Stage III
Cancer has moved outside the uterus to nearby areas. This can include the ovaries, fallopian tubes, vagina, pelvic tissues, or nearby lymph nodes.
Stage IV
Endometrial cancer has spread further. It may involve the bladder or bowel lining, or travel to distant organs such as the lungs or liver.
Outlook and prognosis
Looking ahead can feel daunting, but most people with endometrial cancer do well when it’s found early. Surgery is the main treatment for most, and many return to regular routines within weeks, with follow‑up visits every few months in the first years. Recurrence risk is highest in the first 3 years, then drops; early symptoms of endometrial cancer, like postmenopausal bleeding, often prompt earlier diagnosis, which is one reason outcomes are generally favorable.
Overall survival is strongly tied to stage and tumor type. When cancer is confined to the uterus (stage I), 5‑year survival is commonly above 80–90%. If it has spread to nearby tissues or lymph nodes, survival decreases but many still do well with combined treatments. More aggressive subtypes and cancers that spread to distant organs carry a higher risk, and some people will need long‑term therapy. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle.
Daily life after treatment usually involves routine surveillance and focusing on heart, bone, and metabolic health, especially if hormone levels change after surgery. People living with endometrial cancer often notice fatigue or menopausal symptoms in the first months; these usually improve with time and supportive care. For those with inherited risk, such as Lynch syndrome, targeted screening and earlier evaluation for any bleeding can improve outcomes. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Endometrial cancer can leave lasting effects from the disease itself and from treatments like surgery, radiation, and medicines. Long-term effects vary widely, and not everyone will experience the same changes. Many remember that early symptoms of endometrial cancer—such as unexpected bleeding—helped find the cancer earlier, which can shape long-term outlook. Your care team may follow these areas over time to catch issues early and support recovery.
The cancer can return in the pelvis or elsewhere, most often within the first few years after treatment. Ongoing follow-up visits and scans are used to watch for signs of recurrence.
Removal of the uterus means pregnancy is no longer possible. This can be emotionally significant, especially for people diagnosed at younger ages.
If the ovaries are removed, estrogen levels drop suddenly and can trigger hot flashes, night sweats, and mood shifts. Over time, this can also affect bone strength and heart health.
Vaginal dryness, tightness, or pain can follow surgery or radiation. Desire and comfort may change, and some find intimacy takes more planning and communication.
How is it to live with Endometrial cancer?
Living with endometrial cancer often means moving through a series of phases: diagnosis and treatment decisions, surgery and recovery, and for some, radiation, chemotherapy, or hormonal therapy that can bring fatigue, hot flashes, mood shifts, and changes in sexual health. Daily life may involve more medical visits, planning around energy levels, and attention to vaginal bleeding, pelvic discomfort, or bladder and bowel changes, while coping with worries about fertility, menopause, or recurrence. Many find that honest conversations help partners, family, and friends understand changing needs—whether that’s practical help during recovery, patience with fluctuating energy, or support for intimacy concerns. With a clear care plan, symptom management, and a support network, most people gradually regain routines and a sense of control.
Treatment and drugs
Treatment for endometrial cancer usually starts with surgery to remove the uterus (hysterectomy), often along with the ovaries and fallopian tubes, and sometimes nearby lymph nodes to check for spread. Depending on the stage and grade, doctors may add radiation therapy to lower the risk of the cancer coming back, or use chemotherapy when there’s a higher chance of spread beyond the uterus. For cancers that use hormones to grow, hormone therapy (such as progestins) can help, and some people with advanced or recurrent endometrial cancer may benefit from targeted drugs or immunotherapy based on tumor testing. Not every treatment works the same way for every person, so plans are tailored to the cancer’s features and your health goals. Ask your doctor about the best starting point for you.
Non-drug treatment
Non-drug care for endometrial cancer includes the main treatments—surgery and radiation—plus supportive therapies that ease side effects and rebuild strength. If early symptoms of endometrial cancer led to diagnosis, these approaches aim to remove disease, protect nearby organs, and help you recover well. Non-drug treatments often lay the foundation for long-term health before, during, and after any medicines. Your team will tailor choices to your cancer stage, overall health, and personal goals, including fertility and sexual health.
Most people have a hysterectomy to remove the uterus, often with the fallopian tubes and ovaries. Surgeons may also check lymph nodes to see if endometrial cancer has spread. Minimally invasive approaches can shorten recovery time.
Targeted beams or internal radiation (brachytherapy) treat the uterus and nearby tissues. It can be used after surgery to lower the chance of return, or on its own if surgery isn’t a good option.
Regular checkups look for signs that endometrial cancer has returned and track recovery. Visits may include pelvic exams, symptom review, and sometimes imaging based on your history.
Specialized physical therapy can ease pelvic pain, urinary urgency, or bowel changes after treatment. Gentle exercises and biofeedback can improve control and comfort.
Your genes may have an impact on how drugs work for you
Drugs for endometrial cancer can work differently based on your genes, affecting how you process chemotherapy, hormonal therapy, and targeted agents. Pharmacogenetic testing may guide dosing or drug choice, aiming for better effect with fewer side effects.
Pharmacological treatments
Medicines for endometrial cancer aim to shrink tumors, control spread, and ease symptoms, often alongside surgery or radiation. For many, first-line chemotherapy for endometrial cancer uses carboplatin plus paclitaxel. Options also include hormone therapy and newer immune-targeted treatments chosen by tumor features like hormone receptors, mismatch repair status, and HER2. Not everyone responds to the same medication in the same way.
Standard first choice for advanced or high-risk disease. Given in cycles, it can shrink tumors and lower the chance of recurrence. Side effects may include fatigue, hair loss, and low blood counts.
High-dose medroxyprogesterone acetate or megestrol acetate can slow growth in tumors that carry hormone receptors. Often used for recurrent disease or to preserve fertility in carefully selected early cases. Monitoring includes weight, blood clots risk, and fluid retention.
A hormone-releasing intrauterine device can deliver progestin directly to the lining. In select early, low-grade cases, it may be part of a fertility-sparing approach with close follow-up. It is often combined with oral progestins.
Letrozole or anastrozole lower estrogen levels to help control hormone-sensitive cancer. These are options when progestins are not suitable or have stopped helping. Joint aches and bone thinning can occur over time.
Genetic influences
Most endometrial cancers develop from DNA changes that build up over time and are not inherited. Family history is one of the strongest clues to a genetic influence. A small share—about 3 to 5%—are linked to inherited syndromes such as Lynch syndrome, which involves problems in the body’s DNA repair system and raises lifetime risk of endometrial cancer. Less commonly, conditions like Cowden syndrome (also called PTEN hamartoma tumor syndrome) or rare changes in other repair genes can also increase risk. Because of this, many clinics test endometrial tumors for repair-system changes and, when results point that way, may recommend genetic counseling and genetic testing for endometrial cancer risk. Having an inherited risk means your chances are higher than average, but it does not guarantee you will develop endometrial cancer, and targeted screening and prevention can make a real difference.
Is Endometrial cancer genetic?
Genetics play a meaningful role in endometrial cancer, especially with inherited syndromes like Lynch syndrome. Family history can raise risk, and certain gene variations affect how the cancer starts and grows. Genetic testing may guide screening and treatment choices.
Pharmacogenetics—how genetics influence drug effects
Genetic features of the tumor now guide many treatment choices for endometrial cancer. Alongside medical history and treatment goals, genetic testing can help predict who may benefit from certain medicines. If the cancer shows mismatch repair deficiency or high microsatellite instability, immunotherapy drugs called checkpoint inhibitors are more likely to work. Hormone receptor status (estrogen and progesterone) can steer the use of hormonal treatments, while HER2 changes and rare gene fusions may point to targeted therapies. Some results, such as POLE mutations, can signal a very good outlook and may influence how intensive chemotherapy or radiation needs to be. Separately, personal gene differences that affect how the body breaks down medicines—pharmacogenetic testing for endometrial cancer treatment decisions—can sometimes guide dosing and help lower the risk of side effects for certain chemotherapy or supportive drugs.
Interactions with other conditions
Many living with endometrial cancer also have obesity, polycystic ovary syndrome (PCOS), or type 2 diabetes, which can raise risk and shape both treatment choices and recovery. Doctors call it a “comorbidity” when two conditions occur together. These metabolic conditions can increase surgical and anesthesia risks and may limit the use of certain hormone-based treatments, so teams often tailor care with both cancer control and blood sugar, blood pressure, and weight in mind. In people treated for breast cancer, the medication tamoxifen can raise the chance of endometrial cancer; unexpected vaginal bleeding should be checked, because early symptoms of endometrial cancer can look like menopause changes or fibroids. Some have an inherited condition called Lynch syndrome, linking endometrial cancer with colorectal and ovarian cancers, which is why coordinated screening across these organs is recommended. Interactions can look very different from person to person, and with team-based, coordinated care many live well despite having both endometrial cancer and other health conditions.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described unusual bleeding in midlife as a warning sign, even before the uterus and its lining were well understood. Midwives, community healers, and later physicians noticed that bleeding after menopause often led to serious illness. Families and communities once noticed patterns—an aunt or grandmother who “bled again” years after periods ended and then grew weak—long before the term endometrial cancer existed.
From early theories to modern research, the story of endometrial cancer traces how medicine learned that most cases begin in the lining of the uterus, often after menopause. Nineteenth‑century surgeons began recording cases and outcomes, first describing them by appearance and symptoms. As microscopes improved, pathologists could see differences in cell patterns, separating growths that tended to spread quickly from those that were slower and more confined to the uterus.
With the rise of X‑rays and later ultrasound, doctors could better visualize the uterus without surgery. By the mid‑20th century, biopsies of the uterine lining became routine, allowing earlier diagnosis when people reported postmenopausal bleeding or unusual spotting. In the 1960s and 1970s, researchers recognized that lifetime exposure to estrogen without enough progesterone increased risk. This helped explain why endometrial cancer was more common after years of irregular ovulation, certain hormone therapies, or higher body weight.
Advances in genetics added another layer. Families with inherited conditions that raise the chance of colon cancer were also found to have higher rates of endometrial cancer; this clarified why some relatives across generations shared early symptoms of endometrial cancer such as unexpected bleeding in their 40s or 50s. Over the last three decades, molecular studies have shown that not all endometrial cancers behave the same way. Some have changes in genes that repair DNA, while others have different pathways driving growth. This shifted care from a one‑size‑fits‑all approach to tailored treatment based on tumor features.
Screening the general population never proved helpful, but listening closely to symptoms did. Public health campaigns emphasized that any bleeding after menopause deserves prompt evaluation. Surgeons refined procedures to remove the uterus safely, and radiation and chemotherapy were added when needed. More recently, hormone‑based treatments and targeted therapies, including drugs that help the immune system recognize cancer cells, have improved options for people with advanced disease.
In recent decades, awareness has grown that lifestyle, metabolic health, and access to care shape who is diagnosed and when. This has driven efforts to reduce delays—so that spotting, pelvic discomfort, or changes in discharge are checked early. Today’s understanding of endometrial cancer blends careful attention to symptoms with pathology and genetics, reflecting a long arc of observation, laboratory insight, and steady improvements in diagnosis and care.